Fcpm Iii Services B.V. Purchases 1,112,369 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC)

Fcpm Iii Services B.V. boosted its position in Bicycle Therapeutics plc (NASDAQ:BCYC) by 47.5% in the 4th quarter, Holdings Channel reports. The firm owned 3,452,330 shares of the company’s stock after acquiring an additional 1,112,369 shares during the quarter. Bicycle Therapeutics accounts for about 8.2% of Fcpm Iii Services B.V.’s portfolio, making the stock its 4th largest position. Fcpm Iii Services B.V.’s holdings in Bicycle Therapeutics were worth $48,333,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BCYC. Geode Capital Management LLC grew its holdings in shares of Bicycle Therapeutics by 79.3% during the third quarter. Geode Capital Management LLC now owns 38,335 shares of the company’s stock worth $868,000 after buying an additional 16,958 shares in the last quarter. Principal Financial Group Inc. purchased a new stake in Bicycle Therapeutics during the 3rd quarter valued at about $10,028,000. JPMorgan Chase & Co. raised its holdings in Bicycle Therapeutics by 26.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock valued at $191,000 after acquiring an additional 1,782 shares during the last quarter. Avior Wealth Management LLC acquired a new stake in Bicycle Therapeutics in the 4th quarter valued at about $57,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Bicycle Therapeutics by 30.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company’s stock worth $131,000 after purchasing an additional 2,191 shares in the last quarter. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Stock Performance

Shares of BCYC opened at $8.19 on Friday. Bicycle Therapeutics plc has a 1 year low of $6.10 and a 1 year high of $28.67. The company’s 50-day simple moving average is $8.48 and its 200-day simple moving average is $13.96. The stock has a market capitalization of $566.63 million, a PE ratio of -2.49 and a beta of 1.60.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). The company had revenue of $9.98 million for the quarter, compared to analysts’ expectations of $8.67 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. On average, sell-side analysts predict that Bicycle Therapeutics plc will post -3.06 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BCYC has been the topic of a number of recent research reports. JMP Securities lowered their price objective on Bicycle Therapeutics from $26.00 to $22.00 and set a “market outperform” rating on the stock in a research note on Friday, May 2nd. Needham & Company LLC reissued a “buy” rating and issued a $29.00 price target on shares of Bicycle Therapeutics in a research note on Friday, May 2nd. B. Riley reduced their price target on shares of Bicycle Therapeutics from $17.00 to $14.00 and set a “neutral” rating on the stock in a research report on Friday, May 2nd. HC Wainwright reiterated a “buy” rating and issued a $33.00 price objective on shares of Bicycle Therapeutics in a research report on Wednesday, February 26th. Finally, Royal Bank of Canada decreased their price target on Bicycle Therapeutics from $35.00 to $32.00 and set an “outperform” rating on the stock in a research note on Friday, May 2nd. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.00.

Bicycle Therapeutics Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.